377 related articles for article (PubMed ID: 26932437)
1. CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
van der Woude SO; Hulshof MC; van Laarhoven HW
Chin Clin Oncol; 2016 Feb; 5(1):13. PubMed ID: 26932437
[TBL] [Abstract][Full Text] [Related]
2. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
3. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
5. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
[TBL] [Abstract][Full Text] [Related]
6. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Oppedijk V; van der Gaast A; van Lanschot JJ; van Hagen P; van Os R; van Rij CM; van der Sangen MJ; Beukema JC; Rütten H; Spruit PH; Reinders JG; Richel DJ; van Berge Henegouwen MI; Hulshof MC
J Clin Oncol; 2014 Feb; 32(5):385-91. PubMed ID: 24419108
[TBL] [Abstract][Full Text] [Related]
8. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
[TBL] [Abstract][Full Text] [Related]
13. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
14. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
[TBL] [Abstract][Full Text] [Related]
15. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
[TBL] [Abstract][Full Text] [Related]
16. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
[TBL] [Abstract][Full Text] [Related]
17. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
18. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
19. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
20. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma.
Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP
Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
